Patents by Inventor Christopher Norbert Johnson

Christopher Norbert Johnson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bicyclic heterocycle compounds and their uses in therapy
    Patent number: 11866428
    Abstract: The invention relates to bicyclic heterocycle compounds of formula (I): or tautomeric or stereochemically isomeric forms, N-oxides, pharmaceutically acceptable salts or the solvates thereof; wherein R1, R2a, R2b, R3a, R3b, R5, R6, R7, R8, R9, p and E are as defined herein; to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: September 28, 2020
    Date of Patent: January 9, 2024
    Assignee: ASTEX THERAPEUTICS LIMITED
    Inventors: Alison Jo-Anne Woolford, Steven Howard, Ildiko Maria Buck, Gianni Chessari, Christopher Norbert Johnson, Emiliano Tamanini, James Edward Harvey Day, Elisabetta Chiarparin, Thomas Daniel Heightman, Martyn Frederickson, Charlotte Mary Griffiths-Jones
  • BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY
    Publication number: 20230227450
    Abstract: The invention relates to new bicyclic heterocycle compounds, to pharmaceutical compositions comprising the compounds and to the use of the compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: December 21, 2022
    Publication date: July 20, 2023
    Applicant: ASTEX THERAPEUTICS LIMITED
    Inventors: Gianni CHESSARI, Christopher Norbert JOHNSON, Steven HOWARD, James Edward Harvey DAY, Ildiko Maria BUCK, Charlotte Mary GRIFFITHS-JONES, Gordon SAXTY, Emiliano TAMANINI, Nicola Elizabeth WILSHER
  • Bicyclic heterocycle compounds and their uses in therapy
    Patent number: 11643410
    Abstract: The invention relates to new bicyclic heterocycle compounds, to pharmaceutical compositions comprising the compounds and to the use of the compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: December 7, 2021
    Date of Patent: May 9, 2023
    Assignee: ASTEX THERAPEUTICS LIMITED
    Inventors: Gianni Chessari, Christopher Norbert Johnson, Steven Howard, James Edward Harvey Day, Ildiko Maria Buck, Charlotte Mary Griffiths-Jones, Gordon Saxty, Emiliano Tamanini, Nicola Elizabeth Wilsher
  • HETEROBICYCLIC COMPOUNDS FOR INHIBITING THE ACTIVITY OF SHP2
    Publication number: 20220363693
    Abstract: A compound of formula (I): wherein Ring A, Q, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, X, a, b, c and d are as defined in the specification.
    Type: Application
    Filed: July 23, 2019
    Publication date: November 17, 2022
    Applicants: TAIHO PHARMACEUTICAL CO., LTD., OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Tadashi SHIMAMURA, Ryo KATO, Risako MIURA, Takashi MITA, Takahiro OGAWA, Yufu SAGARA, Christopher Norbert JOHNSON, Steven HOWARD, James Edward Harvey DAY, Jeffrey David ST. DENIS, John Walter LIEBESCHUETZ
  • Pharmaceutical compounds
    Patent number: 11466016
    Abstract: The invention provides new pyrazine derivatives of formula (I): or a tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined herein. The invention also provides pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: October 11, 2022
    Assignees: OTSUKA PHARMACEUTICAL CO., LTD., TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Christopher Norbert Johnson, Ildiko Maria Buck, Gianni Chessari, James Edward Harvey Day, Hideto Fujiwara, Christopher Charles Frederick Hamlett, Steven Douglas Hiscock, Rhian Sara Holvey, Steven Howard, John Walter Liebeschuetz, Nicholas John Palmer, Jeffrey David St Denis, David Geoffrey Twigg, Andrew James Woodhead
  • BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY
    Publication number: 20220204503
    Abstract: The invention relates to new bicyclic heterocycle compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: December 7, 2021
    Publication date: June 30, 2022
    Applicant: ASTEX THERAPEUTICS LIMITED
    Inventors: Gianni CHESSARI, Christopher Norbert JOHNSON, Steven HOWARD, James Edward Harvey DAY, Ildiko Maria BUCK, Charlotte Mary GRIFFITHS-JONES, Gordon SAXTY, Emiliano TAMANINI, Nicola Elizabeth WILSHER
  • PYRAZOLYL QUINOXALINE KINASE INHIBITORS
    Publication number: 20220135544
    Abstract: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: October 20, 2021
    Publication date: May 5, 2022
    Applicant: ASTEX THERAPEUTICS LTD
    Inventors: Gordon SAXTY, Christopher William Murray, Valerio Berdini, Gilbert Ebai Besong, Christopher Charles Frederick Hamlett, Christopher Norbert Johnson, Steven John Woodhead, Michael Reader, David Charles Rees, Laurence Anne Mevellec, Patrick René Angibaud, Eddy Jean Edgard Freyne, Tom Cornelis Hortense Govaerts, Johan Erwin Edmond Weerts, Timothy Pietro Suren Perera, Ronaldus Arnodus Hendrika Joseph Gilissen, Berthold Wroblowski, Jean Fernand Armand Lacrampe, Alexandra Papanikos, Olivier Alexis Georges Querolle, Elisabeth Thérèse Jeanne Pasquier, Isabelle Noëlle Constance Pilatte, Pascal Ghislain André Bonnet, Werner Constant Johan Embrechts, Rhalid Akkari, Lieven Meerpoel
  • ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY
    Publication number: 20220106287
    Abstract: The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.
    Type: Application
    Filed: April 12, 2021
    Publication date: April 7, 2022
    Applicants: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Gianni CHESSARI, Steven HOWARD, Ildiko Maria BUCK, Benjamin David CONS, Christopher Norbert JOHNSON, Rhian Sara HOLVEY, David Charles REES, Jeffrey David ST. DENIS, Emiliano TAMANINI, Bernard Thomas GOLDING, Ian Robert HARDCASTLE, Celine Florence CANO, Duncan Charles MILLER, Martin Edward Mäntylä NOBLE, Roger John GRIFFIN, James Daniel OSBORNE, Joanne PEACH, Arwel LEWIS, Kim Louise HIRST, Benjamin Paul WHITTAKER, David Wyn WATSON, Dale Robert MITCHELL
  • Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity
    Patent number: 11261171
    Abstract: The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: March 1, 2022
    Assignees: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Gianni Chessari, Steven Howard, Ildiko Maria Buck, Benjamin David Cons, Christopher Norbert Johnson, Rhian Sara Holvey, David Charles Rees, Jeffrey David St. Denis, Emiliano Tamanini, Bernard Thomas Golding, Ian Robert Hardcastle, Celine Florence Cano, Duncan Charles Miller, Martin Edward Mäntylä Noble, Roger John Griffin, James Daniel Osborne, Joanne Peach, Arwel Lewis, Kim Louise Hirst, Benjamin Paul Whittaker, David Wyn Watson, Dale Robert Mitchell
  • Bicyclic heterocycle compounds and their uses in therapy
    Patent number: 11225476
    Abstract: The invention relates to new bicyclic heterocycle compounds, to pharmaceutical compositions comprising the compounds and to the use of the compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: January 18, 2022
    Assignee: ASTEX THERAPEUTICS LIMITED
    Inventors: Gianni Chessari, Christopher Norbert Johnson, Steven Howard, James Edward Harvey Day, Ildiko Maria Buck, Charlotte Mary Griffiths-Jones, Gordon Saxty, Emiliano Tamanini, Nicola Elizabeth Wilsher
  • ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY
    Publication number: 20210276984
    Abstract: The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.
    Type: Application
    Filed: February 1, 2021
    Publication date: September 9, 2021
    Applicants: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Gianni CHESSARI, Steven HOWARD, Ildiko Maria BUCK, Benjamin David CONS, Christopher Norbert JOHNSON, Rhian Sara HOLVEY, David Charles REES, Jeffrey David ST. DENIS, Emiliano TAMANINI, Bernard Thomas GOLDING, Ian Robert HARDCASTLE, Celine Florence CANO, Duncan Charles MILLER, Martin Edward Mäntylä NOBLE, Roger John GRIFFIN, James Daniel OSBORNE, Joanne PEACH, Arwel LEWIS, Kim Louise HIRST, Benjamin Paul WHITTAKER, David Wyn WATSON, Dale Robert MITCHELL
  • BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY
    Publication number: 20210122749
    Abstract: The invention relates to bicyclic heterocycle compounds of formula (I): or tautomeric or stereochemically isomeric forms, N-oxides, pharmaceutically acceptable salts or the solvates thereof; wherein R1, R2a, R2b, R3a, R3b, R5, R6, R7, R8, R9, p and E are as defined herein; to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: September 28, 2020
    Publication date: April 29, 2021
    Applicant: ASTEX THERAPEUTICS LIMITED
    Inventors: Alison Jo-Anne WOOLFORD, Steven HOWARD, Ildiko Maria BUCK, Gianni CHESSARI, Christopher Norbert JOHNSON, Emiliano TAMANINI, James Edward Harvey DAY, Elisabetta CHIARPARIN, Thomas Daniel HEIGHTMAN, Martyn FREDERICKSON, Charlotte Mary GRIFFITHS-JONES
  • Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity
    Patent number: 10981898
    Abstract: The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: April 20, 2021
    Assignees: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Gianni Chessari, Steven Howard, Ildiko Maria Buck, Benjamin David Cons, Christopher Norbert Johnson, Rhian Sara Holvey, David Charles Rees, Jeffrey David St. Denis, Emiliano Tamanini, Bernard Thomas Golding, Ian Robert Hardcastle, Celine Florence Cano, Duncan Charles Miller, Martin Edward Mäntylä Noble, Roger John Griffin, James Daniel Osborne, Joanne Peach, Arwel Lewis, Kim Louise Hirst, Benjamin Paul Whittaker, David Wyn Watson, Dale Robert Mitchell
  • PHARMACEUTICAL COMPOUNDS
    Publication number: 20210107908
    Abstract: The invention provides new pyrazine derivatives of formula (I): or a tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined herein. The invention also provides pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: March 1, 2019
    Publication date: April 15, 2021
    Applicants: OTSUKA PHARMACEUTICAL CO., LTD., TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Christopher Norbert JOHNSON, Ildiko Maria BUCK, Gianni CHESSARI, James Edward Harvey DAY, Hideto FUJIWARA, Christopher Charles Frederick HAMLETT, Steven Douglas HISCOCK, Rhian Sara HOLVEY, Steven HOWARD, John Walter LIEBESCHUETZ, Nicholas John PALMER, Jeffrey David ST DENIS, David Geoffrey TWIGG, Andrew James WOODHEAD
  • BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY
    Publication number: 20200325134
    Abstract: The invention relates to new bicyclic heterocycle compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: February 19, 2020
    Publication date: October 15, 2020
    Applicant: ASTEX THERAPEUTICS LIMITED
    Inventors: Gianni CHESSARI, Christopher Norbert JOHNSON, Steven HOWARD, James Edward Harvey DAY, Ildiko Maria BUCK, Charlotte Mary GRIFFITHS-JONES, Gordon SAXTY, Emiliano TAMANINI, Nicola Elizabeth WILSHER
  • ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY
    Publication number: 20200247789
    Abstract: The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.
    Type: Application
    Filed: August 8, 2019
    Publication date: August 6, 2020
    Applicants: ASTEX THERAPEUCTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Gianni CHESSARI, Steven HOWARD, Ildiko Maria BUCK, Benjamin David CONS, Christopher Norbert JOHNSON, Rhian Sara HOLVEY, David Charles REES, Jeffrey David ST. DENIS, Emiliano TAMANINI, Bernard Thomas GOLDING, Ian Robert HARDCASTLE, Celine Florence CANO, Duncan Charles MILLER, Martin Edward Mäntylä NOBLE, Roger John GRIFFIN, James Daniel OSBORNE, Joanne PEACH, Arwel LEWIS, Kim Louise HIRST, Benjamin Paul WHITTAKER, David Wyn WATSON, Dale Robert MITCHELL
  • PYRAZOLYL QUINOXALINE KINASE INHIBITORS
    Publication number: 20200131153
    Abstract: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: October 25, 2019
    Publication date: April 30, 2020
    Applicant: ASTEX THERAPEUTICS LTD
    Inventors: Gordon SAXTY, Christopher William MURRAY, Valerio BERDINI, Gilbert Ebai BESONG, Christopher Charles Frederick HAMLETT, Christopher Norbert JOHNSON, Steven John WOODHEAD, Michael READER, David Charles REES, Laurence Anne MEVELLEC, Patrick René ANGIBAUD, Eddy Jean Edgard FREYNE, Tom Cornelis Hortense GOVAERTS, Johan Erwin Edmond WEERTS, Timothy Pietro Suren PERERA, Ronaldus Arnodus Hendrika Joseph GILISSEN, Berthold WROBLOWSKI, Jean Fernand Armand LACRAMPE, Alexandra PAPANIKOS, Olivier Alexis Georges QUEROLLE, Elisabeth Thérèse Jeanne PASQUIER, Isabelle Noëlle Constance PILATTE, Pascal Ghislain André BONNET, Werner Constant Johan EMBRECHTS, Rhalid AKKARI, Lieven MEERPOEL
  • Bicyclic heterocycle compounds and their uses in therapy
    Patent number: 10618895
    Abstract: The invention relates to new bicyclic heterocycle compounds, to pharmaceutical compositions comprising the compounds and to the use of the compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: April 14, 2020
    Assignee: ASTEX THERAPEUTICS LIMITED
    Inventors: Gianni Chessari, Christopher Norbert Johnson, Steven Howard, James Edward Harvey Day, Ildiko Maria Buck, Charlotte Mary Griffiths-Jones, Gordon Saxty, Emiliano Tamanini, Nicola Elizabeth Wilsher
  • ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY
    Publication number: 20200079761
    Abstract: The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.
    Type: Application
    Filed: August 8, 2019
    Publication date: March 12, 2020
    Applicants: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Gianni CHESSARI, Steven HOWARD, lldiko Maria BUCK, Benjamin David CONS, Christopher Norbert JOHNSON, Rhian Sara HOLVEY, David Charles REES, Jeffrey David ST. DENIS, Emiliano TAMANINI, Bernard Thomas GOLDING, Ian Robert HARDCASTLE, Celine Florence CANO, Duncan Charles MILLER, Martin Edward Mantyla NOBLE, Roger John GRIFFIN, James Daniel OSBORNE, Joanne PEACH, Arwel LEWIS, Kim Louise HIRST, Benjamin Paul WHITTAKER, David Wyn WATSON, Dale Robert MITCHELL
  • Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity
    Patent number: 10544132
    Abstract: The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: January 28, 2020
    Assignees: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Gianni Chessari, Steven Howard, Ildiko Maria Buck, Benjamin David Cons, Christopher Norbert Johnson, Rhian Sara Holvey, David Charles Rees, Jeffrey David St. Denis, Emiliano Tamanini, Bernard Thomas Golding, Ian Robert Hardcastle, Celine Florence Cano, Duncan Charles Miller, Martin Edward Mäntylä Noble, Roger John Griffin, James Daniel Osborne, Joanne Peach, Arwel Lewis, Kim Louise Hirst, Benjamin Paul Whittaker, David Wyn Watson, Dale Robert Mitchell